uniQure N.V. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- uniQure N.V. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $385.00K, a 142.14% increase year-over-year.
- uniQure N.V. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $2.45M, a 19.93% increase year-over-year.
- uniQure N.V. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $8.51M, a 26493.75% increase year-over-year.
- uniQure N.V. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $44.00K.
- uniQure N.V. stock issued during period, value, stock options exercised for fiscal 2025 was $11.16M, a 438.19% increase from fiscal 2024.
- uniQure N.V. stock issued during period, value, stock options exercised for fiscal 2024 was $2.07M, a 1495.38% increase from fiscal 2023.
- uniQure N.V. stock issued during period, value, stock options exercised for fiscal 2023 was $130.00K, a 89.84% decline from fiscal 2022.
- uniQure N.V. stock issued during period, value, stock options exercised for fiscal 2022 was $1.28M, a 51.75% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $385.00K 10-Q · filed 2026-05-05 | $11.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.16M 10-K · filed 2026-03-02 |
| 2025-09-30 | $8.51M 10-Q · filed 2025-11-10 | $10.76M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $44.00K 10-Q · filed 2025-07-29 | $2.28M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $159.00K 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.07M 10-K · filed 2026-03-02 |
| 2024-09-30 | $32.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $130.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $2.00K 10-Q · filed 2024-11-05 | $690.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $34.00K 10-Q · filed 2024-08-01 | $948.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $87.00K 10-Q · filed 2024-05-07 | $943.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.28M 10-K · filed 2025-02-27 |
| 2022-09-30 | $260.00K 10-Q · filed 2023-11-07 | $1.54M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $29.00K 10-Q · filed 2023-08-01 | $2.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $424.00K 10-Q · filed 2023-05-09 | $2.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.65M 10-K · filed 2024-02-28 |
| 2021-09-30 | $914.00K 10-Q · filed 2022-11-02 | $5.48M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $519.00K 10-Q · filed 2022-08-08 | $4.71M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $392.00K 10-Q · filed 2022-05-02 | $6.66M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $7.20M 10-K · filed 2023-02-27 |
| 2020-09-30 | $139.00K 10-Q · filed 2021-10-25 | $5.04M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $2.47M 10-Q · filed 2021-07-26 | $6.08M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $932.00K 10-Q · filed 2021-05-10 | $4.07M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $5.24M 10-K · filed 2022-02-25 |
| 2019-09-30 | $1.18M 10-Q · filed 2020-10-27 | $3.86M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $458.00K 10-Q · filed 2020-07-30 | $4.33M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $2.10M 10-Q · filed 2020-04-29 | $5.30M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.76M 10-K · filed 2021-03-01 |
| 2018-09-30 | $1.65M 10-Q · filed 2019-10-28 | $7.72M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.43M 10-Q · filed 2019-07-29 | $6.17M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.56M 10-Q · filed 2019-04-29 | $5.24M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $4.12M 10-K · filed 2020-03-02 |
| 2017-09-30 | $97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | |
| 2017-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | |
| 2017-03-31 | $441.00K 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $2.58M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $2.87M 10-K · filed 2018-03-14 | |
| 2014-12-31 | $596.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |